01/15
Headlines

NASDAQ:SGEN

Top News: United States Steel Corp. (NYSE:X), Seattle Genetics Inc. (NASDAQ:SGEN), Naugatuck Valley Financial Corporation (NASDAQ:NVSL), National CineMedia (NASDAQ:NCMI), SK Telecom (NYSE:SKM)

Kevin Long03 mins

On Oct 28, United States Steel Corp. (NYSE:X) posted a narrower loss, as revenue increased and the company said U.S. market conditions have remained stable. For the quarter ended Sept. 30, the company posted a loss of $207 million, or $1.42 a share, compared with a loss of $1.79 billion, or $12.38 a share, a…

Read More

Shining on Major News: MannKind Corp. (NASDAQ:MNKD), Exelon Corporation (NYSE:EXC), Coca-Cola Company (NYSE:KO), Seattle Genetics (NASDAQ:SGEN), Yum! Brands, Inc. (NYSE:YUM)

Chris Lewis02 mins

On August 11,2014 MannKind Corp. (NASDAQ:MNKD) reported financial results for the second quarter ended June 30, 2014. For the second quarter of 2014, total operating expenses were $69.8 million, compared to $41.6 million for the second quarter of 2013, an increase of $28.2 million, largely due to an increase in non-cash stock compensation expense of…

Read More

Trending Stocks : Ariad Pharmaceuticals (NASDAQ:ARIA), Checkpoint (NYSE:CKP), Computer Sciences (NYSE:CSC), Seattle Genetics Inc. (NASDAQ:SGEN), Infoblox Inc. (NYSE:BLOX)

Mark Doerr02 mins

US specialty pharma firm Ariad Pharmaceuticals (NASDAQ:ARIA) has granted Israel’s Medison Pharma exclusive rights to commercialize Iclusig (ponatinib) in Israel for patients with Philadelphia-positive (Ph+) leukemias. Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) belongs to Healthcare sector. Its weekly performance is -12.09%. On last trading day company shares ended up $5.38. Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) distance from 50-day…

Read More

Biotech Stocks: Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), Prosensa Holding NV (NASDAQ:RNA), Agios Pharmaceuticals Inc (NASDAQ:AGIO), Seattle Genetics, Inc. (NASDAQ:SGEN), Idera Pharmaceuticals Inc (NASDAQ:IDRA)

Adam Keintzel03 mins

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) on July 9 announced the pricing of its underwritten public offering of 2,017,349 shares of its common stock at a price to the public of $40.00 per share, before underwriting discounts. Ultragenyx is selling 1,311,277 shares of its common stock in this offering, and certain selling stockholders are selling 706,072 shares…

Read More

Biotech Insider Selling: Achillion Pharmaceuticals (NASDAQ:ACHN), Questcor Pharmaceuticals(NASDAQ:QCOR), Seattle Genetics (NASDAQ:SGEN), Repligen Corporation (NASDAQ:RGEN), bluebird bio (NASDAQ:BLUE)

Mark DeFrance03 mins

Achillion Pharmaceuticals Inc (NASDAQ:ACHN) major shareholder Qvt Associates Gp Llc sold 128,649 shares of the company’s stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $7.66, for a total transaction of $985,451.34. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) stock performance was -6.32% in last session and finished the day…

Read More

Biotech Insider Buying: Seattle Genetics (NASDAQ:SGEN), Corcept Therapeutics Incorporated (NASDAQ:CORT), Cytori Therapeutics (NASDAQ:CYTX), Oramed Pharmaceuticals (NASDAQ:ORMP), Biota Pharmaceuticals (NASDAQ:BOTA)

John Bellich03 mins

Seattle Genetics, Inc (NASDAQ:SGEN) Director Felix Baker purchased 281,963 shares of Seattle Genetics stock in a transaction dated Wednesday, June 4th. The stock was purchased at an average price of $34.86 per share, for a total transaction of $9,829,230.18. Following the transaction, the director now directly owns 76,997 shares of the company’s stock, valued at…

Read More